All In Biotech

Drug Trial Radar · NCT03816345

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jul 16, 2019

Primary completion

Mar 30, 2028

Study completion Mar 30, 2028

Sponsor

Sponsor type
NIH
First posted
Jan 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced), to other places in the body (metastatic) or cannot removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Chemotherapy drugs, such as platinum containing therapies and fluoropyrimidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab alone and in combination with other treatments, including ipilimumab, cabozantinib, platinum containing therapy, or fluoropyrimidine, may be safe, tolerable, and/or effective in treating patients with autoimmune disorders and advanced, metastatic, or unresectable cancer.

Conditions

  • Autoimmune Disease
  • Crohn Disease
  • Dermatomyositis
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Inflammatory Bowel Disease
  • Malignant Solid Neoplasm
  • Multiple Sclerosis
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Sjogren Syndrome
  • Systemic Lupus Erythematosus
  • Systemic Scleroderma
  • Ulcerative Colitis

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of blood, CSF, tissue, stool and urine samples

  • CabozantinibDrug

    Given PO

  • FluoropyrimidineDrug

    Given fluoropyrimidine

  • IpilimumabBiological

    Given IV

  • NivolumabBiological

    Given IV

  • Platinum CompoundDrug

    Given platinum containing chemotherapy

  • Platinum DoubletDrug

    Given platinum doublet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: Up to 100 days after completion of study treatment
  2. Change in disease assessmentsTime frame: Baseline up to 100 days after completion of study treatment
  3. Overall response rateTime frame: Up to 5 years after completion of study treatment
  4. Changes in serum chemokines and circulating immune cells over timeTime frame: Baseline up to 100 days after completion of study treatment
  5. Gene expression in normal tissuesTime frame: Up to 100 days after completion of study treatment
  6. Clinical measures of interestTime frame: Up to 100 days after completion of study treatment

Locations

52 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Active not recruiting

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California · Active not recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Smilow Cancer Center/Yale-New Haven Hospital

    New Haven, Connecticut · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia · Active not recruiting

  • Northwestern University

    Chicago, Illinois · Active not recruiting

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Active not recruiting

  • University of Kansas Clinical Research Center

    Fairway, Kansas · Recruiting

  • HaysMed

    Hays, Kansas · Recruiting

  • University of Kansas Cancer Center

    Kansas City, Kansas · Recruiting

  • Lawrence Memorial Hospital

    Lawrence, Kansas · Recruiting

  • The University of Kansas Cancer Center - Olathe

    Olathe, Kansas · Recruiting

  • University of Kansas Cancer Center-Overland Park

    Overland Park, Kansas · Recruiting

  • University of Kansas Hospital-Indian Creek Campus

    Overland Park, Kansas · Recruiting

  • Mercy Hospital Pittsburg

    Pittsburg, Kansas · Suspended

  • Salina Regional Health Center

    Salina, Kansas · Recruiting

  • University of Kansas Health System Saint Francis Campus

    Topeka, Kansas · Recruiting

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas · Recruiting

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland · Recruiting

  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda, Maryland · Recruiting

  • National Institutes of Health Clinical Center

    Bethesda, Maryland · Active not recruiting

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Wayne State University/Karmanos Cancer Institute

    Detroit, Michigan · Active not recruiting

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri · Recruiting

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri · Recruiting

  • University Health Truman Medical Center

    Kansas City, Missouri · Recruiting

  • University of Kansas Cancer Center - North

    Kansas City, Missouri · Recruiting

  • University of Kansas Cancer Center - Lee's Summit

    Lee's Summit, Missouri · Recruiting

  • University of Kansas Cancer Center at North Kansas City Hospital

    North Kansas City, Missouri · Suspended

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Siteman Cancer Center-South County

    St Louis, Missouri · Recruiting

  • Siteman Cancer Center at Christian Hospital

    St Louis, Missouri · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • NYU Langone Hospital - Long Island

    Mineola, New York · Recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York · Recruiting

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

    New York, New York · Recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.